Navigation Links
SOM Biotech Licenses its First Product and Expands to the United States
Date:7/25/2017

BARCELONA, Spain and CAMBRIDGE, Massachusetts, July 25, 2017 /PRNewswire/ -- The med-tech biopharmaceutical company SOM Biotech, specializing in repurposing drugs to treat rare nervous system diseases, has concluded a worldwide license agreement with Corino Therapeutics Inc. to clinically develop and market the drug SOM0226 against transthyretin amyloidosis (ATTR). Before this licensing agreement had been reached, the drug achieved very promising results in a Phase 2 study conducted in Europe.

A new office in the United States

The office, located in Cambridge, Massachusetts, is managed by Michael Greenberg. Mr Greenberg is a recognised expert in business development in the healthcare industry, with more than 20 years of experience in negotiating international alliances and managing cutting-edge biopharmaceutical companies in the United States, Europe and Asia.

Series A fundraising

The geographic expansion, and the clinical development of SOM's most advanced assets, will be capitalized through the licensing revenues from SOM0226, as well as the commencing Series A fundraising, targeted to leading US and European venture investors.

SOM Biotech will dedicate the resources secured to conduct the next clinical trials and expand the company pipeline through its platform technology; SOM3355 is a drug indicated for chorea movements associated to Huntington's disease and tardive dyskinesia, and SOM1201 has shown clinical evidence of efficacy for Adrenoleukodystrophy (ALD) and potentially Adrenomyeloneuropathy (AMN).

This injection of capital will also allow the biopharmaceutical company to channel plenty of resources into its expansion into the North American market. Initially, its activity will be centred on promoting licensing projects and partnerships on the field of repurposing drugs for rare neurological diseases.

Altogether, since it was created in 2009, the company has raised more than $6 million from public and private capital.

Dr Raúl Insa, SOM's founder and CEO, went on to say, "SOM is entering an aggressive international growth stage to become the world's leading company in drug repurposing. We have made it past the initial business concept stage with our first licence and are now pushing into the clinics the next two products, while expanding the pipeline. Our major challenges are getting our leading products to reach the market in the next 5 years and build a sustainable business model realizing the value that investors are expecting from this company."

About SOM Biotech

SOM Biotech Ltd. (www.sombiotech.com) is a med-tech biopharmaceutical company founded in 2009 in Barcelona (Spain) with a business and expanding presence in Cambridge, Massachusetts (United States). The company's business strategy consists of identifying, clinically developing and marketing drugs to treat rare neurological diseases, using drugs already on the market (repurposing).

SOM has an extensive portfolio of products that includes drugs for rare diseases (Huntington's disease, Adrenoleukodystrophy, Glioblastoma and Duchenne Muscular Dystrophy) as well other drugs for different therapeutic areas.

The company is also engaging in repurposing collaborations with major pharmaceutical companies by supporting them in developing the drugs in their portfolios and through partnership agreements.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/som-biotech-licenses-its-first-product-and-expands-to-the-united-states-300492904.html


'/>"/>
SOURCE SOM Biotech
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. TNI BioTech, Inc. Corporations CEO Issues Letter to Shareholders Discussing Recent Events
2. Sony Biotechnology Inc.s New Technology for Science Provides Researchers Results in Color
3. TNI BioTech, Inc. Stock to Begin Trading on the OTCQB Marketplace
4. Goodwin Biotechnology Announces Process Development Sub-Contract for an Anthrax Vaccine
5. MRI Interventions CEO to Present at 2013 Brain Tumor Biotech Summit regarding MRI-Guided Therapies for Brain Cancer
6. TNI BioTech, Inc. Announces Mandatory Exchange of Common Stock Certificates CUSIP Number 872608104 for New Stock Certificates with Active CUSIP 872608203
7. Evaluate Report to Examine Life After the Patent Cliff, Provides Analysis on Pharmaceutical and Biotech Markets and Consensus Forecasts to 2018
8. Mid-Atlantic Biotech Leaders Featured On BioSpace Map
9. Platine Pharma Services et Indicia Biotechnology se rapprochent pour renforcer leur leadership en immunomonitoring
10. ResearchMoz.us: Biotechnology Market By Application (Biopharmacy, Bioservices, Bioagri, Bioindustrial), By Technology (Fermentation, Tissue Regeneration, PCR, Nanobiotechnology, DNA Sequencing & Others) - Global Industry Analysis, Size, Share, Growt
11. The Galien Foundation Announces 2013 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... FRISCO, Texas , Oct. 11, 2017 /PRNewswire/ ... healthcare services, has amplified its effort during National ... patients about hereditary cancer risks. ... Journal of Clinical Oncology calculated that more than ... to have inherited mutations in BRCA1 or BRCA2 and ...
(Date:10/7/2017)... Oct. 6, 2017   Provista, a proven ... $100 billion in purchasing power, today announced a new ... The Newsroom is the online home for ... infographics, expert bios, news releases, slideshows and events. ... a wealth of resources at their fingertips, viewers can ...
(Date:10/4/2017)... , Oct. 4, 2017 ... single-use, self-contained, illuminating medical devices, today announced regulatory ... Health Surveillance Agency (or Agência Nacional de Vigilância ... first single-use, cordless surgical retractor with integrated LED ... optimal access, illumination and exposure of a tissue ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... The American Board of Family Medicine's (ABFM) Board of Directors has selected Warren ... James C. Puffer upon his retirement. Dr. Newton will serve in the position of ... end of 2018. Upon assuming the role of President and CEO on January 1, ...
(Date:10/13/2017)... ... 2017 , ... Apple Rehab Shelton Lakes , which specializes in the ... facility as part of a disaster drill on October 3rd. , Apple Rehab participated ... Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid Plan ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris F. ... AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking place ... the field of medical informatics, this prestigious award is presented to an individual whose ...
Breaking Medicine News(10 mins):